[go: up one dir, main page]

MA33571B1 - Traitement de cellules tumorales astrocytaires avec des inhibiteurs de recepteurs d'endotheline - Google Patents

Traitement de cellules tumorales astrocytaires avec des inhibiteurs de recepteurs d'endotheline

Info

Publication number
MA33571B1
MA33571B1 MA34671A MA34671A MA33571B1 MA 33571 B1 MA33571 B1 MA 33571B1 MA 34671 A MA34671 A MA 34671A MA 34671 A MA34671 A MA 34671A MA 33571 B1 MA33571 B1 MA 33571B1
Authority
MA
Morocco
Prior art keywords
treatment
endotylene
astrocytes
receptor inhibitors
macitentan
Prior art date
Application number
MA34671A
Other languages
Arabic (ar)
English (en)
Inventor
Sun-Jin Kim
Isaiah J Fidler
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42938154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33571(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Publication of MA33571B1 publication Critical patent/MA33571B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A61N5/1084—Beam delivery systems for delivering multiple intersecting beams at the same time, e.g. gamma knives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

La description concerne un antagoniste de récepteur d'endothéline à utiliser dans la prévention ou le traitement de métastases cérébrales en combinaison avec un agent cytotoxique de chimiothérapie, la radiothérapie ou les deux. L'antagoniste de récepteur d'endothéline peut être par exemple, le bosentan, le macitentan ou un mélange de bosentan et de macitentan.
MA34671A 2009-08-10 2012-03-08 Traitement de cellules tumorales astrocytaires avec des inhibiteurs de recepteurs d'endotheline MA33571B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23268709P 2009-08-10 2009-08-10
PCT/US2010/044832 WO2011019630A2 (fr) 2009-08-10 2010-08-09 Traitement de cellules tumorales astrocytaires avec des inhibiteurs de récepteurs d’endothéline

Publications (1)

Publication Number Publication Date
MA33571B1 true MA33571B1 (fr) 2012-09-01

Family

ID=42938154

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34671A MA33571B1 (fr) 2009-08-10 2012-03-08 Traitement de cellules tumorales astrocytaires avec des inhibiteurs de recepteurs d'endotheline

Country Status (27)

Country Link
US (2) US8999934B2 (fr)
EP (1) EP2464218B1 (fr)
JP (1) JP2013501791A (fr)
KR (1) KR20120088665A (fr)
CN (1) CN102510719B (fr)
AU (1) AU2010282744B2 (fr)
BR (1) BR112012003103A2 (fr)
CA (1) CA2770397A1 (fr)
CL (1) CL2012000333A1 (fr)
DK (1) DK2464218T3 (fr)
EA (1) EA023864B1 (fr)
ES (1) ES2543280T3 (fr)
HR (1) HRP20150890T1 (fr)
HU (1) HUE026005T2 (fr)
IL (1) IL217915A0 (fr)
IN (1) IN2012DN01261A (fr)
MA (1) MA33571B1 (fr)
MX (1) MX2012001562A (fr)
NZ (1) NZ598078A (fr)
PL (1) PL2464218T3 (fr)
PT (1) PT2464218E (fr)
SG (1) SG178828A1 (fr)
SI (1) SI2464218T1 (fr)
TN (1) TN2012000054A1 (fr)
TW (1) TWI483938B (fr)
WO (1) WO2011019630A2 (fr)
ZA (1) ZA201200980B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2670405B1 (fr) * 2011-02-04 2015-09-02 Actelion Pharmaceuticals Ltd. Combinaisons contenant du macitentan destinees au traitement du glioblastoma multiforme
US9132281B2 (en) 2011-06-21 2015-09-15 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
KR102623404B1 (ko) * 2015-03-06 2024-01-11 비욘드스프링 파마수티컬스, 인코포레이티드. 뇌 종양 치료 방법
BR112017018954A2 (pt) 2015-03-06 2018-05-15 Beyondspring Pharmaceuticals, Inc. uso de forma mutante de proteína ras e método para tratar câncer
ES2910035T3 (es) 2015-07-13 2022-05-11 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina
WO2017024032A2 (fr) 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions et procédés pour traiter des cancers associés à l'activation d'etbr
JP6996728B2 (ja) * 2016-01-07 2022-01-17 学校法人自治医科大学 グルコーストランスポーター１発現用アデノ随伴ウイルスベクター
CN108778267A (zh) 2016-02-08 2018-11-09 万春药业公司 包含妥卡雷琐或其类似物的组合物
JP7122499B2 (ja) * 2016-06-03 2022-08-22 幸久 村田 がん転移阻害剤
MX389200B (es) 2016-06-06 2025-03-20 Beyondspring Pharmaceuticals Inc Composición y método para reducir la neutropenia.
WO2018129381A1 (fr) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Composés se liant à la tubuline et leur usage thérapeutique
MX2019009020A (es) 2017-02-01 2019-11-12 Beyondspring Pharmaceuticals Inc Metodo para reducir la neutropenia.
JP7374769B2 (ja) 2017-02-15 2023-11-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｎｋ細胞を活性化するための組成物及び方法
AU2019206652B2 (en) 2018-01-12 2024-11-14 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
AU2019212118A1 (en) 2018-01-24 2020-09-03 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
CN109232546B (zh) 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
CN113874364B (zh) 2019-05-22 2024-04-05 无锡智康弘义生物科技有限公司 一种嘧啶磺酰胺类化合物的晶型及其制备方法
CN112062857B (zh) * 2019-06-10 2024-08-09 鸿运华宁（杭州）生物医药有限公司 Eta抗体与bnp的融合蛋白质，及其药物组合物和应用
WO2021062027A1 (fr) * 2019-09-25 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Entrée thalamique sur le cortex orbitofrontal entraînant une inhibition cérébrale dépendante de la fréquence, médiée par le gaba et la zona incerta
US20240197723A1 (en) 2021-04-09 2024-06-20 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227984B8 (en) * 2000-12-18 2007-01-04 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
CN101262847B (zh) 2005-09-12 2010-11-24 埃科特莱茵药品有限公司 包含嘧啶-磺酰胺的稳定性医药组合物
ES2446303T3 (es) 2008-02-20 2014-03-07 Actelion Pharmaceuticals Ltd. Combinación que comprende paclitaxel para el tratamiento del cáncer de ovarios
EP2670405B1 (fr) 2011-02-04 2015-09-02 Actelion Pharmaceuticals Ltd. Combinaisons contenant du macitentan destinees au traitement du glioblastoma multiforme

Also Published As

Publication number Publication date
AU2010282744A1 (en) 2012-03-22
HK1171336A1 (en) 2013-03-28
EA201270264A1 (ru) 2013-02-28
CN102510719B (zh) 2015-07-22
SG178828A1 (en) 2012-04-27
US20120144510A1 (en) 2012-06-07
ZA201200980B (en) 2012-10-31
TWI483938B (zh) 2015-05-11
EP2464218B1 (fr) 2015-05-27
ES2543280T3 (es) 2015-08-17
KR20120088665A (ko) 2012-08-08
AU2010282744B2 (en) 2014-08-28
NZ598078A (en) 2013-07-26
PT2464218E (pt) 2015-09-16
JP2013501791A (ja) 2013-01-17
TN2012000054A1 (en) 2013-09-19
HUE026005T2 (en) 2016-04-28
PL2464218T3 (pl) 2015-12-31
BR112012003103A2 (pt) 2016-04-19
CA2770397A1 (fr) 2011-02-17
DK2464218T3 (en) 2015-07-20
SI2464218T1 (sl) 2015-10-30
MX2012001562A (es) 2013-01-29
IL217915A0 (en) 2012-03-29
IN2012DN01261A (fr) 2015-05-15
TW201109315A (en) 2011-03-16
HRP20150890T1 (hr) 2015-09-25
WO2011019630A2 (fr) 2011-02-17
US20150352113A1 (en) 2015-12-10
EA023864B1 (ru) 2016-07-29
WO2011019630A3 (fr) 2011-06-03
CL2012000333A1 (es) 2013-01-25
CN102510719A (zh) 2012-06-20
US8999934B2 (en) 2015-04-07
EP2464218A2 (fr) 2012-06-20

Similar Documents

Publication Publication Date Title
MA33571B1 (fr) Traitement de cellules tumorales astrocytaires avec des inhibiteurs de recepteurs d'endotheline
MX2009009304A (es) Inhibidores de cinasa pim y metodos para su uso.
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
MA31663B1 (fr) Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe
PH12013501244A1 (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MA52856B1 (fr) Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
CL2011003347A1 (es) Composicion farmaceutica que comprende un conjugado, correspondiente a benzoato de hidrocodona ; y uso en el tratamiento de una enfermedad, trastorno o afeccion mediada por la union de un opioide a receptores opioides.
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
ME01532B (me) Jedinjenja
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
BR112013008140A8 (pt) "compostos imidazotriazinona".
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
MY163886A (en) Substituted benzimidazoles as kinase inhibitors
MA32132B1 (fr) Utilisation de ranolazine pour traiter la douleur
BR112015020466A2 (pt) inibidores de cdc7
MA35753B1 (fr) Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA38218A1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
MX2010001449A (es) Bromhidrato de bupropion y aplicaciones terapeuticas.
EA202091356A1 (ru) A2a АНТАГОНИСТЫ КАК УСИЛИТЕЛИ КОГНИТИВНОЙ И МОТОРНОЙ ФУНКЦИЙ
BR112012014235A2 (pt) tiazóis bicíclicos como moduladores alostéricos de receptores mglur5